DexCom is a medical devices business based in the US. DexCom shares (DXCM) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $75.88 – an increase of 8.46% over the previous week. DexCom employs 9,500 staff and has a trailing 12-month revenue of around $4 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $75.88 |
|---|---|
| 52-week range | $62.34 - $142.00 |
| 50-day moving average | $69.89 |
| 200-day moving average | $102.89 |
| Wall St. target price | $95.31 |
| PE ratio | 43.9294 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $1.70 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $74.68 from 2024-11-14
| 1 week (2024-11-08) | 6.75% |
|---|---|
| 1 month (2024-10-16) | 6.84% |
| 3 months (2024-08-16) | 0.04% |
| 6 months (2024-05-16) | -43.39% |
| 1 year (2023-11-16) | -28.72% |
|---|---|
| 2 years (2022-11-16) | -35.00% |
| 3 years (2021-11-16) | 162.0075 |
| 5 years (2019-11-15) | 43.36% |
Valuing DexCom stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of DexCom's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
DexCom's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 44x. In other words, DexCom shares trade at around 44x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
DexCom's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.1341. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into DexCom's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
DexCom's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $840.4 million.
The EBITDA is a measure of a DexCom's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $4 billion |
|---|---|
| Operating margin TTM | 15.29% |
| Gross profit TTM | $1.9 billion |
| Return on assets TTM | 6.06% |
| Return on equity TTM | 32.06% |
| Profit margin | 17.22% |
| Book value | $5.07 |
| Market Capitalization | $29.2 billion |
TTM: trailing 12 months
We're not expecting DexCom to pay a dividend over the next 12 months.
DexCom's shares were split on a 4:1 basis on 12 June 2022 . So if you had owned 1 share the day before before the split, the next day you'd have owned 4 shares. This wouldn't directly have changed the overall worth of your DexCom shares – just the quantity. However, indirectly, the new 75% lower share price could have impacted the market appetite for DexCom shares which in turn could have impacted DexCom's share price.
Over the last 12 months, DexCom's shares have ranged in value from as little as $62.34 up to $142. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while DexCom's is 1.173. This would suggest that DexCom's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
DexCom, Inc. , a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators.
Modak has no monthly fee, but it’s slim on features. Greenlight starts at $5.99 but is a value for big families.
Get the capital your business needs to grow with repayments that adapt to your revenue.
We’ve compared the best cash advance apps for quick cash — find the right one for your needs.
A review of Beyond Finance, a company that offers debt settlement and consolidation loans.
1. Make a budget 2. Create a savings plan 3. Automate savings 4. Pay yourself first 5. Use a high-yield account 6. Do a savings challenge…
To save $10K: 1. Automate savings 2. Invest 3. Budget 4. Open a high-yield savings account 5. Cut down on spending 6. Pay off debt…
A review of Arrowhead Advance, a tribal lender that charges interest rates up to 830% and has numerous bad reviews.
There aren’t many personal loans with no credit check. True no credit check loans include cash advance apps, payday loans and more.
Compare business cash advances from a variety of lenders and the pros and cons of each option.
Top picks for loans like Lendumo, with more competitive rates and a range of options for borrowers of all kinds.